Bicalutamide is an anti-androgen that is used worldwide to treat prostate cancer (CaP). However, there are no data on blood bicalutamide concentrations in hemodialysis (HD) patients with CaP. Therefore, we investigated the plasma levels of bicalutamide during the peridialysis period in this population. The study group included 5 HD patients with CaP who had been treated with bicalutamide (80 mg/day) for at least 3 months. Blood samples were taken during and between HD sessions and the plasma concentrations of the active R enantiomer (R-bicalutamide) were assessed using an HPLC assay. The plasma R-bicalutamide levels on the non-dialysis day were measured in 2 patients (patients 1 and 2) immediately before dosing and 8 and 24 h after dosing. These levels were 18,730, 19,090 and 19,420 ng/ml (patient 1), and 4,522, 4,581, and 5,296 ng/ml (patient 2), respectively. The mean plasma levels of R-bicalutamide in all 5 subjects just before HD, and 2 and 4 h after the start of HD were 8,726, 9,354 and 10,068 ng/ml, respectively. These results show that bicalutamide does not accumulate and is not diluted in the blood circulation of HD patients when given at the normal dosage used in the general population.

Keywords:
Anti-androgen, Bicalutamide, Hemodialysis, Pharmacokinetics, Prostate cancer
1.
Kamata T, Fushimi K: Prevalence of prostate cancer in end-stage renal disease patients. Urol Int 2008;80:419–424.
2.
Lin HF, Li YH, Wang CH, Chou CL, Kuo DJ, Fang TC: Increased risk of cancer in chronic dialysis patients: a population-based cohort study in Taiwan. Nephrol Dial Transplant 2012;27:1585–1590.
3.
Akaza H, Yamaguti A, Matsuda T, et al: Superior anti-tumor efficacy of bicalutamide 80 mg in combination with a luteinizing hormone-releasing hormone (LHRH) agonist versus LHRH agonist monotherapy as first-line treatment for advanced prostate cancer: interim results of a randomized study in Japanese patients. Jpn J Clin Oncol 2004;34:20–28.
4.
Cockshott ID, Cooper KJ, Sweetmore DS, Blacklock NJ, Denis L: The pharmacokinetics of Casodex in prostate cancer patients after single and during multiple dosing. Eur Urol 1990;18:10–17.
5.
Furr BJA, Blackledge GRP, Cockshott ID: Casodex: preclinical and clinical studies; in Pasqualini JR, Katzenellenbogen BS (eds): Hormone-Dependent Cancer. New York, Dekker, 1996, pp 397–424.
6.
McKillop D, Boyle GW, Cockshott ID, Jones DC, Phillips PJ, Yates RA: Metabolism and enantioselective pharmacokinetics of Casodex in man. Xenobiotica 1993;23:1241–1253.
7.
Cockshott ID, Plummer GF, Cooper KJ, Warwick MJ: The pharmacokinetics of Casodex in laboratory animals. Xenobiotica 1991;21:1347–1355.
8.
Tyrrell CJ, Denis L, Newling D, Soloway M, Channer K, Cockshott ID: Casodex 10–200 mg daily, used as monotherapy for the treatment of patients with advanced prostate cancer: an overview of the efficacy, tolerability and pharmacokinetics from three phase II dose-ranging studies. Eur Urol 1998;33:39–53.
© 2012 S. Karger AG, Basel
2012
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.